Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
Status: Enrolling
Updated:  12/31/1969
Facility 1
mi
from
Toms River, NJ
Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
Status: Enrolling
Updated: 12/31/1969
Facility 1
mi
from
Toms River, NJ
Click here to add this to my saved trials
Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
Status: Enrolling
Updated:  12/31/1969
Facility 2
mi
from
Toms River, NJ
Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
Status: Enrolling
Updated: 12/31/1969
Facility 2
mi
from
Toms River, NJ
Click here to add this to my saved trials
Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
Status: Enrolling
Updated:  12/31/1969
Facility 1
mi
from
Charlotte, NC
Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
Status: Enrolling
Updated: 12/31/1969
Facility 1
mi
from
Charlotte, NC
Click here to add this to my saved trials
Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
Status: Enrolling
Updated:  12/31/1969
Facility 1
mi
from
Raleigh, NC
Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
Status: Enrolling
Updated: 12/31/1969
Facility 1
mi
from
Raleigh, NC
Click here to add this to my saved trials
Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
Status: Enrolling
Updated:  12/31/1969
Facility 1
mi
from
Norristown, PA
Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
Status: Enrolling
Updated: 12/31/1969
Facility 1
mi
from
Norristown, PA
Click here to add this to my saved trials
Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
Status: Enrolling
Updated:  12/31/1969
Facility 1
mi
from
Willow Grove, PA
Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
Status: Enrolling
Updated: 12/31/1969
Facility 1
mi
from
Willow Grove, PA
Click here to add this to my saved trials
Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
Status: Enrolling
Updated:  12/31/1969
Facility 1
mi
from
Columbia, SC
Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
Status: Enrolling
Updated: 12/31/1969
Facility 1
mi
from
Columbia, SC
Click here to add this to my saved trials
Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
Status: Enrolling
Updated:  12/31/1969
Eisai Trial Site 1
mi
from
Fujisawa,
Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
Status: Enrolling
Updated: 12/31/1969
Eisai Trial Site 1
mi
from
Fujisawa,
Click here to add this to my saved trials
Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
Status: Enrolling
Updated:  12/31/1969
Facility #1
mi
from
Springdale, AR
Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
Status: Enrolling
Updated: 12/31/1969
Facility #1
mi
from
Springdale, AR
Click here to add this to my saved trials
Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
Status: Enrolling
Updated:  12/31/1969
Facility #1
mi
from
La Jolla, CA
Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
Status: Enrolling
Updated: 12/31/1969
Facility #1
mi
from
La Jolla, CA
Click here to add this to my saved trials
Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
Status: Enrolling
Updated:  12/31/1969
Meridien Research
mi
from
Lakeland, FL
Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
Status: Enrolling
Updated: 12/31/1969
Meridien Research
mi
from
Lakeland, FL
Click here to add this to my saved trials
Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
Status: Enrolling
Updated:  12/31/1969
Facility 2
mi
from
Tampa, FL
Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
Status: Enrolling
Updated: 12/31/1969
Facility 2
mi
from
Tampa, FL
Click here to add this to my saved trials
Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
Status: Enrolling
Updated:  12/31/1969
Facility 1
mi
from
Macon, GA
Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
Status: Enrolling
Updated: 12/31/1969
Facility 1
mi
from
Macon, GA
Click here to add this to my saved trials
Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
Status: Enrolling
Updated:  12/31/1969
Nevada Senior Services (NSS) Adult Day Care Center
mi
from
Henderson, NV
Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
Status: Enrolling
Updated: 12/31/1969
Nevada Senior Services (NSS) Adult Day Care Center
mi
from
Henderson, NV
Click here to add this to my saved trials
Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
Status: Enrolling
Updated:  12/31/1969
Facility 1
mi
from
Las Vegas, NV
Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
Status: Enrolling
Updated: 12/31/1969
Facility 1
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Study to Assess the Pharmacokinetics and Safety of DBSF in Adult Subjects With Epilepsy
A Multi-Center, Open Label, Cross-Over Study to Assess the Pharmacokinetics and Safety of Diazepam Buccal Soluble Film (DBSF) in Adult Subjects With Epilepsy
Status: Enrolling
Updated:  12/31/1969
On Site Clinical Solutions, LLC
mi
from
Charlotte, NC
Study to Assess the Pharmacokinetics and Safety of DBSF in Adult Subjects With Epilepsy
A Multi-Center, Open Label, Cross-Over Study to Assess the Pharmacokinetics and Safety of Diazepam Buccal Soluble Film (DBSF) in Adult Subjects With Epilepsy
Status: Enrolling
Updated: 12/31/1969
On Site Clinical Solutions, LLC
mi
from
Charlotte, NC
Click here to add this to my saved trials
Study to Assess the Pharmacokinetics and Safety of DBSF in Adult Subjects With Epilepsy
A Multi-Center, Open Label, Cross-Over Study to Assess the Pharmacokinetics and Safety of Diazepam Buccal Soluble Film (DBSF) in Adult Subjects With Epilepsy
Status: Enrolling
Updated:  12/31/1969
Arizona Health Sciences Center
mi
from
Tucson, AZ
Study to Assess the Pharmacokinetics and Safety of DBSF in Adult Subjects With Epilepsy
A Multi-Center, Open Label, Cross-Over Study to Assess the Pharmacokinetics and Safety of Diazepam Buccal Soluble Film (DBSF) in Adult Subjects With Epilepsy
Status: Enrolling
Updated: 12/31/1969
Arizona Health Sciences Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Study to Assess the Pharmacokinetics and Safety of DBSF in Adult Subjects With Epilepsy
A Multi-Center, Open Label, Cross-Over Study to Assess the Pharmacokinetics and Safety of Diazepam Buccal Soluble Film (DBSF) in Adult Subjects With Epilepsy
Status: Enrolling
Updated:  12/31/1969
Rancho Research Institute
mi
from
Downey, CA
Study to Assess the Pharmacokinetics and Safety of DBSF in Adult Subjects With Epilepsy
A Multi-Center, Open Label, Cross-Over Study to Assess the Pharmacokinetics and Safety of Diazepam Buccal Soluble Film (DBSF) in Adult Subjects With Epilepsy
Status: Enrolling
Updated: 12/31/1969
Rancho Research Institute
mi
from
Downey, CA
Click here to add this to my saved trials
Study to Assess the Pharmacokinetics and Safety of DBSF in Adult Subjects With Epilepsy
A Multi-Center, Open Label, Cross-Over Study to Assess the Pharmacokinetics and Safety of Diazepam Buccal Soluble Film (DBSF) in Adult Subjects With Epilepsy
Status: Enrolling
Updated:  12/31/1969
Yale University School of Medicine-Comprehensive Epilepsy Center
mi
from
New Haven, CT
Study to Assess the Pharmacokinetics and Safety of DBSF in Adult Subjects With Epilepsy
A Multi-Center, Open Label, Cross-Over Study to Assess the Pharmacokinetics and Safety of Diazepam Buccal Soluble Film (DBSF) in Adult Subjects With Epilepsy
Status: Enrolling
Updated: 12/31/1969
Yale University School of Medicine-Comprehensive Epilepsy Center
mi
from
New Haven, CT
Click here to add this to my saved trials
Study to Assess the Pharmacokinetics and Safety of DBSF in Adult Subjects With Epilepsy
A Multi-Center, Open Label, Cross-Over Study to Assess the Pharmacokinetics and Safety of Diazepam Buccal Soluble Film (DBSF) in Adult Subjects With Epilepsy
Status: Enrolling
Updated:  12/31/1969
Hawaii Pacific Neuroscience
mi
from
Honolulu, HI
Study to Assess the Pharmacokinetics and Safety of DBSF in Adult Subjects With Epilepsy
A Multi-Center, Open Label, Cross-Over Study to Assess the Pharmacokinetics and Safety of Diazepam Buccal Soluble Film (DBSF) in Adult Subjects With Epilepsy
Status: Enrolling
Updated: 12/31/1969
Hawaii Pacific Neuroscience
mi
from
Honolulu, HI
Click here to add this to my saved trials
Study to Assess the Pharmacokinetics and Safety of DBSF in Adult Subjects With Epilepsy
A Multi-Center, Open Label, Cross-Over Study to Assess the Pharmacokinetics and Safety of Diazepam Buccal Soluble Film (DBSF) in Adult Subjects With Epilepsy
Status: Enrolling
Updated:  12/31/1969
Mid-Atlantic Epilepsy and Sleep Center
mi
from
Bethesda, MD
Study to Assess the Pharmacokinetics and Safety of DBSF in Adult Subjects With Epilepsy
A Multi-Center, Open Label, Cross-Over Study to Assess the Pharmacokinetics and Safety of Diazepam Buccal Soluble Film (DBSF) in Adult Subjects With Epilepsy
Status: Enrolling
Updated: 12/31/1969
Mid-Atlantic Epilepsy and Sleep Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Study to Assess the Pharmacokinetics and Safety of DBSF in Adult Subjects With Epilepsy
A Multi-Center, Open Label, Cross-Over Study to Assess the Pharmacokinetics and Safety of Diazepam Buccal Soluble Film (DBSF) in Adult Subjects With Epilepsy
Status: Enrolling
Updated:  12/31/1969
Saint Peter's University Hospital
mi
from
New Brunswick, NJ
Study to Assess the Pharmacokinetics and Safety of DBSF in Adult Subjects With Epilepsy
A Multi-Center, Open Label, Cross-Over Study to Assess the Pharmacokinetics and Safety of Diazepam Buccal Soluble Film (DBSF) in Adult Subjects With Epilepsy
Status: Enrolling
Updated: 12/31/1969
Saint Peter's University Hospital
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Study to Assess the Pharmacokinetics and Safety of DBSF in Adult Subjects With Epilepsy
A Multi-Center, Open Label, Cross-Over Study to Assess the Pharmacokinetics and Safety of Diazepam Buccal Soluble Film (DBSF) in Adult Subjects With Epilepsy
Status: Enrolling
Updated:  12/31/1969
Univ of Rochester Medical Center
mi
from
Rochester, NY
Study to Assess the Pharmacokinetics and Safety of DBSF in Adult Subjects With Epilepsy
A Multi-Center, Open Label, Cross-Over Study to Assess the Pharmacokinetics and Safety of Diazepam Buccal Soluble Film (DBSF) in Adult Subjects With Epilepsy
Status: Enrolling
Updated: 12/31/1969
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Study to Assess the Pharmacokinetics and Safety of DBSF in Adult Subjects With Epilepsy
A Multi-Center, Open Label, Cross-Over Study to Assess the Pharmacokinetics and Safety of Diazepam Buccal Soluble Film (DBSF) in Adult Subjects With Epilepsy
Status: Enrolling
Updated:  12/31/1969
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Study to Assess the Pharmacokinetics and Safety of DBSF in Adult Subjects With Epilepsy
A Multi-Center, Open Label, Cross-Over Study to Assess the Pharmacokinetics and Safety of Diazepam Buccal Soluble Film (DBSF) in Adult Subjects With Epilepsy
Status: Enrolling
Updated: 12/31/1969
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study to Assess the Pharmacokinetics and Safety of DBSF in Adult Subjects With Epilepsy
A Multi-Center, Open Label, Cross-Over Study to Assess the Pharmacokinetics and Safety of Diazepam Buccal Soluble Film (DBSF) in Adult Subjects With Epilepsy
Status: Enrolling
Updated:  12/31/1969
Austin Epilepsy Care Center
mi
from
Austin, TX
Study to Assess the Pharmacokinetics and Safety of DBSF in Adult Subjects With Epilepsy
A Multi-Center, Open Label, Cross-Over Study to Assess the Pharmacokinetics and Safety of Diazepam Buccal Soluble Film (DBSF) in Adult Subjects With Epilepsy
Status: Enrolling
Updated: 12/31/1969
Austin Epilepsy Care Center
mi
from
Austin, TX
Click here to add this to my saved trials
Study to Assess the Pharmacokinetics and Safety of DBSF in Adult Subjects With Epilepsy
A Multi-Center, Open Label, Cross-Over Study to Assess the Pharmacokinetics and Safety of Diazepam Buccal Soluble Film (DBSF) in Adult Subjects With Epilepsy
Status: Enrolling
Updated:  12/31/1969
VCU Medical Center
mi
from
Richmond, VA
Study to Assess the Pharmacokinetics and Safety of DBSF in Adult Subjects With Epilepsy
A Multi-Center, Open Label, Cross-Over Study to Assess the Pharmacokinetics and Safety of Diazepam Buccal Soluble Film (DBSF) in Adult Subjects With Epilepsy
Status: Enrolling
Updated: 12/31/1969
VCU Medical Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase II, Open-Label, Extension Study to Assess the Safety and Efficacy of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated:  12/31/1969
Lurie Children's Hospital
mi
from
Chicago, IL
Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase II, Open-Label, Extension Study to Assess the Safety and Efficacy of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated: 12/31/1969
Lurie Children's Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase II, Open-Label, Extension Study to Assess the Safety and Efficacy of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase II, Open-Label, Extension Study to Assess the Safety and Efficacy of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase II, Open-Label, Extension Study to Assess the Safety and Efficacy of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Richmond at VCU
mi
from
Richmond, VA
Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase II, Open-Label, Extension Study to Assess the Safety and Efficacy of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Richmond at VCU
mi
from
Richmond, VA
Click here to add this to my saved trials
Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase II, Open-Label, Extension Study to Assess the Safety and Efficacy of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated:  12/31/1969
Alberta Children's Hospital
mi
from
Calgary,
Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase II, Open-Label, Extension Study to Assess the Safety and Efficacy of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated: 12/31/1969
Alberta Children's Hospital
mi
from
Calgary,
Click here to add this to my saved trials
Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase II, Open-Label, Extension Study to Assess the Safety and Efficacy of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated:  12/31/1969
UC Davis
mi
from
Sacramento, CA
Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase II, Open-Label, Extension Study to Assess the Safety and Efficacy of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated: 12/31/1969
UC Davis
mi
from
Sacramento, CA
Click here to add this to my saved trials
Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase II, Open-Label, Extension Study to Assess the Safety and Efficacy of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated:  12/31/1969
Washington University
mi
from
Saint Louis, MO
Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase II, Open-Label, Extension Study to Assess the Safety and Efficacy of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated: 12/31/1969
Washington University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Autism Biomarker Consortium for Clinical Trials
Autism Biomarker Consortium for Clinical Trials
Status: Enrolling
Updated:  12/31/1969
Yale University Child Study Center
mi
from
New Haven, CT
Autism Biomarker Consortium for Clinical Trials
Autism Biomarker Consortium for Clinical Trials
Status: Enrolling
Updated: 12/31/1969
Yale University Child Study Center
mi
from
New Haven, CT
Click here to add this to my saved trials
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated:  12/31/1969
Barrow Neurological Institute
mi
from
Phoenix, AZ
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated: 12/31/1969
Barrow Neurological Institute
mi
from
Phoenix, AZ
Click here to add this to my saved trials
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated:  12/31/1969
Uc Irvine Medical Center
mi
from
Orange, CA
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated: 12/31/1969
Uc Irvine Medical Center
mi
from
Orange, CA
Click here to add this to my saved trials
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated:  12/31/1969
Forbes Norris MDA/ALS Research Center - California Pacific Medical Center
mi
from
San Francisco, CA
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated: 12/31/1969
Forbes Norris MDA/ALS Research Center - California Pacific Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated:  12/31/1969
University of Florida Medical Center
mi
from
Gainesville, FL
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated: 12/31/1969
University of Florida Medical Center
mi
from
Gainesville, FL
Click here to add this to my saved trials
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated:  12/31/1969
Carol and Frank Morsini Center for Advanced Health Care - University of South Florida
mi
from
Tampa, FL
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated: 12/31/1969
Carol and Frank Morsini Center for Advanced Health Care - University of South Florida
mi
from
Tampa, FL
Click here to add this to my saved trials
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated:  12/31/1969
Emory University Hospital
mi
from
Atlanta, GA
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated: 12/31/1969
Emory University Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated:  12/31/1969
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated: 12/31/1969
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated:  12/31/1969
University of Kentucky Medical Center
mi
from
Lexington, KY
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated: 12/31/1969
University of Kentucky Medical Center
mi
from
Lexington, KY
Click here to add this to my saved trials
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated:  12/31/1969
Ochsner Neuroscience Institute
mi
from
New Orleans, LA
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated: 12/31/1969
Ochsner Neuroscience Institute
mi
from
New Orleans, LA
Click here to add this to my saved trials
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins Hospital
mi
from
Baltimore, MD
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated:  12/31/1969
University of Massachusetts Memorial Medical Center
mi
from
Worcester, MA
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated: 12/31/1969
University of Massachusetts Memorial Medical Center
mi
from
Worcester, MA
Click here to add this to my saved trials
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated:  12/31/1969
University of Michigan Medical Center
mi
from
Ann Arbor, MI
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated: 12/31/1969
University of Michigan Medical Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated:  12/31/1969
Hennepin County Medical Center
mi
from
Minneapolis, MN
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated: 12/31/1969
Hennepin County Medical Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated:  12/31/1969
Washington University Medical Center
mi
from
Saint Louis, MO
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated: 12/31/1969
Washington University Medical Center
mi
from
Saint Louis, MO
Click here to add this to my saved trials
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated:  12/31/1969
Neurology Associates PC
mi
from
Lincoln, NE
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated: 12/31/1969
Neurology Associates PC
mi
from
Lincoln, NE
Click here to add this to my saved trials
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated:  12/31/1969
Mount Sinai Beth Israel
mi
from
New York, NY
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Status: Enrolling
Updated: 12/31/1969
Mount Sinai Beth Israel
mi
from
New York, NY
Click here to add this to my saved trials